Ann: Appendix 4D and Half Year Report, page-42

Axovant is not a big pharma. It doesn't have a product revenue stream. How long do you think it can fund Benitec's R&D before it needs to raise more capital? If Parkinson's is a flop (not saying it will be), what do you think that will do to the company's capacity to raise capital? What do you think the flow on effect of that will be?

On the flip side, a positive Parkinson's result should see a share price rise in both Axovant and companies associated with it.